Tyrosine kinases in inflammatory dermatologic disease

J Am Acad Dermatol. 2011 Aug;65(2):389-403. doi: 10.1016/j.jaad.2010.04.026. Epub 2010 Jun 26.

Abstract

Tyrosine kinases (TKs) are enzymes that catalyze the phosphorylation of tyrosine residues on protein substrates. They are key components of signaling pathways that drive an array of cellular responses including proliferation, differentiation, migration, and survival. Specific TKs have recently been identified as critical to the pathogenesis of several autoimmune and inflammatory diseases. Small-molecule inhibitors of TKs are emerging as a novel class of therapy that may provide benefit in certain patient subsets. In this review, we highlight TK signaling implicated in inflammatory dermatologic diseases, evaluate strategies aimed at inhibiting these aberrant signaling pathways, and discuss prospects for future drug development.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Biomarkers / metabolism
  • Dermatitis / drug therapy*
  • Dermatitis / enzymology*
  • Dermatitis / physiopathology
  • Dermatomyositis / drug therapy
  • Dermatomyositis / enzymology
  • Dermatomyositis / physiopathology
  • Drug Delivery Systems
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Phosphorylation
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / metabolism*
  • Risk Assessment
  • Scleroderma, Systemic / drug therapy
  • Scleroderma, Systemic / enzymology
  • Scleroderma, Systemic / physiopathology
  • Signal Transduction
  • Treatment Outcome

Substances

  • Biomarkers
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases